There is new medical research concerning pancreatic cancer linked to diabetes medicines in the DPP-4 inhibitor drug class. In more detail, the use of dipeptidyl peptidase-4 inhibitors (DPP-4i) diabetes medicines may be associated with an increased risk for pancreatic cancer in patients with newly diagnosed type 2 diabetes. This finding comes … [Read more...]
Questions Raised About Whether Fournier’s Gangrene Is A Side Effect Of Farxiga, Invokana, And Jardiance
At the recent American Diabetes Association (ADA) Scientific Sessions there were reportedly questions raised about whether there is an increased risk of Fournier’s gangrene when using Farxiga as well as other SGLT2 inhibitor diabetes drugs such as Invokana and Jardiance. From this July 18, 2019 article published online by Medscape, “Fournier … [Read more...]
Cases Of Fournier Gangrene Associated With Diabetes Drugs Invokana, Jardiance, And Farxiga
The FDA has identified 55 unique cases of Fournier gangrene associated with diabetes drugs in the Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors class between March 1, 2013 and January 31, 2019. Of those Fournier gangrene cases, 21 cases were associated with Invokana (canagliflozin), 18 cases were associated with Jardiance (empagliflozin), and … [Read more...]
New SGLT2 Inhibitor Diabetes Drugs to Hit the Market in January
Approval On December 19, 2017, the FDA approved Merck & Co. and Pfizer's new diabetes drug, Steglatro, and its two combination versions, Steglujan and Segluromet. These drugs are classified as sodium/glucose cotransporter 2 (SGLT2) inhibitors, and will be available this coming January. Steglatro consists of ertugliflozin, while Steglujan … [Read more...]
New Analysis Finds An Increased Risk Of Bladder Cancer For Jardiance
This article, “SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials”, was published in the October 2017 edition of Diabetologia. It presents the findings of medical researchers who conducted a systematic literature review to identify randomized controlled trials that reported … [Read more...]
SGLT2 Inhibitors May Have an Increased Risk of Acute Renal Failure
SGLT2 Inhibitors: A New Side Effect In previous articles, I have discussed SGLT2 inhibitor diabetes drugs such as Invokana, Farxiga, and Jardiance and the adverse events associated with them. Such side effects include diabetic ketoacidosis (DKA) and lower-limb amputations. A recent study identified a new possible side effect of these drugs … [Read more...]
J&J Tries to Expand Invokana Label to Include Cardiovascular Benefits
Johnson & Johnson's, the drug manufacturer of diabetes drugs Invokana, Invokamet, and Invokamet XR, recently submitted a supplemental new drug application (sNDA) to the FDA to request expansion of the labels for these drugs. If granted, the new label would include a cardiovascular indication concerning the reduction of risk of cardiovascular … [Read more...]
Type 2 Diabetes Drugs Linked to Severe Joint Pain
Health Canada recently warned about the risk of severe, debilitating joint pain as a result of taking type 2 diabetes medications called dipeptidylpeptidase-4 (DPP-4) inhibitors. This DPP-4 inhibitors class of drugs includes the following: Onglyza Kombiglyze XR Nesina Kazano Oseni Glyxambi Janumet (XR) Januvia … [Read more...]